Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

Bristol-Myers Squibb (BMS) building

BMS chases after Roche in EU bladder cancer race

Opdivo set to go head-to-head with Tecentriq

- PMLiVE

Merck closes in on first-line NSCLC label for Keytruda in US

Accelerated FDA review could see PD-1 inhibitor approved by the end of the year

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

A stumble, but not a fall – what’s next for Opdivo?

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

Blue Latitude Health

Bristol-Myers Squibb (BMS) building

BMS rocked by Opdivo failure in lung cancer

PD-1 inhibitor phase III trial reveals disappointing results

- PMLiVE

Keytruda cleared in Europe for lung cancer

New second-line indication for Merck’s drug puts it in direct competition with BMS’ Opdivo

Bristol-Myers Squibb (BMS) building

NICE finalises record-breaking Opdivo/Yervoy appraisal

BMS’s immunotherapy combination receives recommendation in 24 days

Wearables’ impact on cancer patients’ quality of life to be tested

Project sees the Memorial Sloan Kettering Cancer Center collaborate with Medidata

Celgene building

Jounce bags $225m upfront in Celgene immuno-oncology deal

Five pipeline candidate agreement worth up to $2.5bn should Celgene claim the rights

Bristol-Myers Squibb (BMS) building

Opdivo moves closer to head and neck cancer approval

Possible US verdict by November for BMS’ ‘breakthrough’ SCCHN therapy

Bristol-Myers Squibb (BMS) building

SMC gives green light for BMS’ Opdivo

Scotland will be first UK country to access the drug after NICE refusal

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links